1. Home
  2. INDP vs AIHS Comparison

INDP vs AIHS Comparison

Compare INDP & AIHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.41

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

AIHS

Senmiao Technology Limited

HOLD

Current Price

$1.16

Market Cap

5.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
INDP
AIHS
Founded
2000
2014
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.2M
5.7M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
INDP
AIHS
Price
$2.41
$1.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
67.1K
14.4K
Earning Date
05-11-2026
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
14.63
EPS
N/A
N/A
Revenue
N/A
$3,389,072.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.25
52 Week High
$13.24
$8.26

Technical Indicators

Market Signals
Indicator
INDP
AIHS
Relative Strength Index (RSI) 45.22 43.35
Support Level $2.36 $1.10
Resistance Level $3.11 $1.28
Average True Range (ATR) 0.41 0.10
MACD -0.07 -0.01
Stochastic Oscillator 25.71 16.63

Price Performance

Historical Comparison
INDP
AIHS

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About AIHS Senmiao Technology Limited

Senmiao Technology Ltd is a holding company. Along with its subsidiaries, it is engaged in facilitating automobile transactions and offering related services. The group's business activities include providing car rental services to individual customers with lease term no more than twelve months; leasing and servicing of new energy vehicles; offering services to automobile purchasers throughout the purchase process; providing management and related services to Partner Platforms and other companies; automobile financing; and providing other related supporting services to customers. The majority of the group's revenue is generated from its automobile rental business.

Share on Social Networks: